Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$0.42 - $0.65 $101,698 - $157,391
-242,140 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$0.54 - $2.74 $130,755 - $663,463
242,140 New
242,140 $146,000
Q2 2020

Aug 17, 2020

SELL
$1.45 - $4.3 $30,657 - $90,914
-21,143 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$0.75 - $2.55 $145,649 - $495,207
-194,199 Reduced 90.18%
21,143 $34,000
Q4 2019

Feb 14, 2020

SELL
$1.65 - $2.48 $94,261 - $141,677
-57,128 Reduced 20.97%
215,342 $534,000
Q3 2019

Nov 14, 2019

BUY
$1.48 - $2.52 $202,680 - $345,103
136,946 Added 101.05%
272,470 $458,000
Q2 2019

Aug 13, 2019

BUY
$2.45 - $3.32 $290,043 - $393,038
118,385 Added 690.73%
135,524 $339,000
Q1 2019

May 14, 2019

SELL
$2.52 - $3.24 $67,881 - $87,275
-26,937 Reduced 61.11%
17,139 $53,000
Q4 2018

Feb 14, 2019

SELL
$1.92 - $4.1 $200,519 - $428,191
-104,437 Reduced 70.32%
44,076 $116,000
Q3 2018

Nov 14, 2018

BUY
$3.39 - $4.61 $118,727 - $161,456
35,023 Added 30.86%
148,513 $640,000
Q2 2018

Aug 14, 2018

SELL
$1.89 - $4.95 $132,218 - $346,287
-69,957 Reduced 38.13%
113,490 $447,000
Q1 2018

May 15, 2018

SELL
$2.06 - $2.38 $13,390 - $15,470
-6,500 Reduced 3.42%
183,447 $380,000
Q4 2017

Feb 13, 2018

BUY
$1.91 - $2.83 $5,500 - $8,150
2,880 Added 1.54%
189,947 $399,000
Q3 2017

Nov 14, 2017

BUY
$2.44 - $2.91 $215,639 - $257,177
88,377 Added 89.55%
187,067 $501,000
Q2 2017

Nov 09, 2017

BUY
N/A
98,690
98,690 $236,000

Others Institutions Holding MEIP

# of Institutions
1
Shares Held
2K
Call Options Held
0
Put Options Held
0

About MEI Pharma, Inc.


  • Ticker MEIP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 133,261,000
  • Market Cap $370M
  • Description
  • MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...
More about MEIP
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.